HMNC (Holsboer / Maschmeyer) (Group)

https://www.hmnc.de

HMNC Brain Health (HMNC Holding GmbH) is a clinical stage precision psychiatry biopharma company, pioneering the development of personalized therapies, powered by its AI platform and predictive companion diagnostics suite, bringing substantial therapeutic benefit to select patient populations suffering from mental health disorders. The company develops a unique pipeline for targeting both Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD). HMNC’s precision psychiatry franchise for MDD includes the Nelivabon program, in which it develops a V1bR antagonist with its companion diagnostic, and the Cortibon program, in which it develops a CRHR1 antagonist with its companion diagnostic. Additionally, in a joint venture with Develco Pharma, the Company is also developing an oral-prolonged release formulation of racemic ketamine that combines the rapid efficacy of ketamine with superior tolerability and convenience, to provide an enhanced treatment option for TRD. The Company has operations in both the US and Germany and is backed by a renowned global VC, several family offices, and a strategic healthcare investor. *

	Start	2010-12-01 established
	Industry	biomarker
	Industry 2	neurology
	Person	Holsboer, Florian (MPI of Psychiatry + Neuronova Pharmaceuticals AG founder)
	Person 2	Maschmeyer, Carsten (AWD)

	Region	München (Munich)
	Country	Germany
	Street	20 Wilhelm-Wagenfeld-Str.
	City	80807 München
	Tel	+49-89-36090-200
		Address record changed: 2021-08-16

Basic data	Employees	n. a.

		* Document for »About Section«: HMNC Holding GmbH. (10/20/22). "Press Release: HMNC Brain Health Raises EUR 14.3 million to Advance Precision Psychiatry Therapies". Munich.

		Record changed: 2023-12-30